The Globe and Mail reports in its Saturday, June 11, edition that insiders at Knight Therapeutics have been buying company shares. The Globe's regular guest columnist Ted Dixon writes in the Who Is Buying and Selling column that he has been watching for insider buying in the health care sector. He says drug marketer Knight Therapeutics caught his eye. He says insiders have been buying shares as the stock consolidates under $6. In fact, Mr. Dixon says insiders have spent over half a million dollars picking up shares in the public market so far this year. From Jan. 4 to May 18, six insiders bought a total of 107,655 common shares at an average price of $5.20. The buying was led by president, director and chief executive officer Samira Sakhia, who bought 39,305 shares. The Globe reported on Sept. 24 that Stifel analyst Justin Keywood had upgraded Knight Therapeutics to "buy" from "hold." Mr. Keywood said he expected to see "strength" when Knight Therapeutics reported its third quarter financial results in November. The shares could then be had for $5.46.